Nice technology appraisal
NICE's decision on whether a specific medicine should be available on the NHS in England.
Also called: technology appraisal, ta, nice ta, nice approval, nice guidance
Related words clinical trial
Topics Medicines
NICE's decision on whether a specific medicine should be available on the NHS in England.
Also called: technology appraisal, ta, nice ta, nice approval, nice guidance
Related words clinical trial
Topics Medicines
NICE's guidance for GPs suggests a full blood count (to look for anaemia and other signs), inflammation markers such as CRP and ESR, kidney and liver tests including albumin, iron, B12, folate and vitamin D levels, and a coeliac test to rule that out. Crohn's & Colitis UK explains that CRP rises with inflammation but can be normal even when the gut is inflamed, so blood tests are used alongside other tests rather than on their own.
Sources
The 2025 BSG guideline does not suggest routinely stopping advanced therapy, because about a third of people relapse within one to two years of stopping, even after the gut has healed. It says any decision should be made jointly with your IBD team, with close monitoring afterwards. NICE appraisals also ask for regular reviews of whether ongoing treatment is still needed. Never stop a medicine without speaking to your team.
Sources
The NHS suggests asking your doctor or a patient organisation about trials you may be eligible for. You can also search the NIHR's Be Part of Research website for UK studies and contact research teams directly. Registries such as ISRCTN and ClinicalTrials.gov list studies and their results. Crohn's & Colitis UK explains how new medicines are tested before they are licensed.
Sources
Nobody knows exactly. The NHS and Crohn's & Colitis UK say the immune system goes wrong and attacks the gut. Researchers think it happens in people whose genes make them susceptible, combined with things in the environment and the bacteria living in the gut. NICE's GP summary lists family history, smoking and a recent bout of gastroenteritis as factors linked to a higher risk. NICE describes Crohn's as non-infectious, so it is not something you can catch from someone.
Sources
Upadacitinib is a tablet that belongs to a group called JAK inhibitors. It blocks proteins inside cells that switch on the immune response, rather than being an antibody given by drip or injection. Trials found it worked better than placebo for moderate to severe Crohn's, and NICE recommends it after a biologic has failed or when anti-TNFs are unsuitable. Shingles was more common in people taking it.
Sources
NICE's appraisal allowing mirikizumab (Omvoh) to be used for adults with moderate to severe Crohn's disease after a previous biologic has not worked or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor
NICE's appraisal recommending risankizumab (Skyrizi) for people aged 16 and over with moderate to severe Crohn's disease after a previous biologic has failed or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor biological treatment
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics Biologics and newer medicines Medicines
Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy
NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.
Topics Biologics and newer medicines Medicines
Jargon explained anti-TNF TNF-alpha inhibitor patient access scheme moderately to severely active
NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.
Topics Biologics and newer medicines Medicines
Jargon explained IL-23 inhibitor TNF-alpha inhibitor conventional treatment
NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.
Topics Monitoring Biologics and newer medicines
Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF
NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.
Topics Biologics and newer medicines Medicines
Jargon explained anti-TNF biosimilar conventional therapy severe active Crohn's disease
NICE guidance recommending the faecal calprotectin poo test to help tell inflammatory bowel disease apart from non-inflammatory conditions such as IBS.
Topics Diagnosis and tests Monitoring
Jargon explained faecal calprotectin irritable bowel syndrome
NICE's current guidance on the SeHCAT scan, which replaced its 2012 guidance (DG7). NICE says there is not yet enough evidence to recommend SeHCAT for routine use, including for people with Crohn's who have not had part of the ileum removed and have long-lasting diarrhoea, but hospitals already using it can carry on while collecting more data.
Topics Diagnosis and tests Toilet habits
Jargon explained SeHCAT bile acid diarrhoea ileal resection
NICE's recommendation that a faecal calprotectin poo test can be used to help doctors tell IBD apart from IBS. For adults with recent lower gut symptoms it applies when cancer is not suspected and proper quality checks and local pathways are in place; it is also recommended for children with suspected IBD who have been referred to a specialist. This guidance was first published as DG11 and NICE has since renumbered it HTG320 without changing it.
Topics Diagnosis and tests
Jargon explained faecal calprotectin inflammatory bowel disease irritable bowel syndrome
NICE's diagnostics guidance on the SeHCAT scan for diarrhoea caused by bile acid malabsorption, including in people with Crohn's disease who have not had part of the ileum removed.
Topics Diagnosis and tests Toilet habits
Jargon explained sehcat scan bile acid malabsorption ileum
NICE's summary for GPs on Crohn's, describing it as a long-term, relapsing and remitting inflammatory condition of the gut that is not an infection. It is organised into when to suspect Crohn's, which tests to arrange, what else it might be, and how to manage suspected and confirmed cases in primary care.
Topics About Crohn's disease Diagnosis and tests Flare-ups Complications
Jargon explained relapsing-remitting inflammation primary care inflammatory bowel disease flare-up